Inside the ICE House

Latest Episodes:

AI x Bio Series: Inceptive CEO Jakob Uszkoreit on Designing Medicines That Work Like Life Itself Aug 31, 2026

Show notes

Inceptive CEO Jakob Uszkoreit goes Inside the ICE House to challenge the foundational assumptions of modern drug discovery, arguing that AI will enable medicines that work with the body's natural complexity rather than against it. He discusses Inceptive's partnership with Alnylam Pharmaceuticals and why their RNA interference platform and rich data history make them a uniquely powerful AI collaborator. Uszkoreit explains why partnerships are essential for a small company with broadly applicable technology, and why the long-term prize is therapies that are gentler, earlier, and truly personalized.

AI x Bio Series: Formation Bio CEO Ben Liu on Fixing the Bottleneck Slowing Down Medicine Aug 27, 2026

Show notes

Formation Bio is rewriting the rules of drug development at a time when AI is accelerating drug discovery far faster than the industry can bring new therapies to patients. CEO Ben Liu goes Inside the ICE House to explain why the real bottleneck in pharma isn't finding promising drug candidates, it's developing them efficiently and at scale. He unpacks Formation Bio's AI-native model, which acquires already-discovered drugs and deploys proprietary tools to optimize trial design, predict clinical outcomes, and identify overlooked disease indications.

ETF Central: Horizon Head of Product Clark Allen Aug 26, 2026

Show notes

Clark Allen, Head of Product at Horizon Investments, joins Bilal Little on ETF Central to discuss the firm's rapid growth to more than $4 billion in ETF assets and its advisor-first approach to product development. Allen shares his journey from CPA and quantitative researcher to leading Horizon's expanding ETF platform, highlighting the firm's use of systematic, options-based strategies to help advisors manage risk and client expectations. He also discusses recent acquisitions in equity and fixed income, the evolving role of financial advisors, and his outlook for continued innovation across the ETF industry.

Episode 550: Third Coast Bank CEO Bart Caraway on Putting People and Purpose Into Banking Aug 24, 2026

Show notes

Third Coast Bancshares Founder and CEO Bart Caraway joins Inside the ICE House to discuss building a Texas-based community bank from a vision into a publicly traded company now listed on the New York Stock Exchange. He reflects on launching the bank in 2008 at the onset of the Great Recession and how a commitment to servant leadership and community impact has driven the bank's growth. He also highlights the bank's dual listing on NYSE Texas, sharing his enthusiasm for the listing and the exchange as a symbol of the state's expanding economic influence and entrepreneurial spirit.

NYSE Texas: Finance of America's Michael Fant on Reversing the Reverse Mortgage Mindset Aug 19, 2026

Show notes

Finance of America SVP of Finance Michael Fant joins Inside the ICE House to discuss how the company has grown into the largest originator and servicer of reverse mortgages in the United States, helping seniors tap into their home equity to fund retirement. He shares how Finance of America has shifted the perception of reverse mortgages from a product of last resort to a sophisticated financial planning tool, expanding its offerings to include jumbo and second-lien products. He explains the company's deep commitment to consumer education and how technology is being carefully integrated to improve efficiency while preserving the human touch points seniors rely on.

AI x Bio Series: Ginkgo Bioworks CEO Jason Kelly on Engineering Life's Next Operating System Aug 17, 2026

Show notes

Ginkgo Bioworks CEO Jason Kelly joins Inside the ICE House to explain how Ginkgo is building the infrastructure to make biology programmable at scale — automating the lab work that has long bottlenecked scientific progress and offering experimentation as a cloud-based service to pharma, agriculture, and academic researchers. Kelly also details how a landmark collaboration with OpenAI demonstrated that AI can now autonomously design and iterate on biological experiments, pointing toward a future where the $120 billion spent annually on manual research gets dramatically more productive.

Episode 549: Guardian Metal Resources CEO Oliver Friesen on America's Tungsten Crisis Aug 13, 2026

Show notes

The United States has not operated a single tungsten mine in over a decade, leaving the nation dangerously dependent on foreign countries for a metal critical to defense, semiconductors, and manufacturing. CEO Oliver Friesen goes Inside the ICE House to detail how Guardian Metal Resources is racing to bring two Nevada tungsten mines into commercial production before the end of 2028. He discusses China's sweeping export ban, the national security stakes of domestic supply chains, and how partnerships with the Department of War and Montana Mining Association are accelerating progress.

ETF Central: MarketGrader Founder & CEO Carlos Diez Aug 12, 2026

Show notes

Carlos Diez, CEO and founder of MarketGrader, joins Bilal Little on ETF Central to discuss his firm's fundamentals-driven approach to index investing and how it bridges the gap between active and passive strategies. Diez shares his journey from Colombia to founding MarketGrader in 1999, built around a 24-factor rating system that historically designates only 15% of covered companies as a buy. He highlights the Barron's 400 ETF as a core equity holding designed to reduce concentration risk through equal weighting across high-quality U.S. companies, and closes by framing AI as a broad economic enabler rather than a narrow market trade.

AI x Bio Series: Takeda CSO Chris Arendt on Transforming Drug Discovery & the R&D Pipeline Aug 10, 2026

Show notes

Takeda is entering one of the most pivotal moments in its 245-year history, with a late-stage pipeline poised to transform patient outcomes across three therapeutic areas. Chief Scientific Officer Chris Arendt goes Inside the ICE House to discuss the science behind drug candidates targeting narcolepsy, polycythemia vera, and psoriasis. He explores how AI and computational technologies are reshaping drug discovery and why building the right data foundation is critical to supercharging Takeda's R&D engine.

James Rutledge Shares Six Decades of History Inside the NYSE Aug 05, 2026

Show notes

Longtime New York Stock Exchange member and former Director James Rutledge goes Inside the ICE House to reflect on a remarkable career that began with a help wanted sign on Wall Street in 1968. He shares firsthand stories from the paperwork crisis, the transition from pneumatic tubes and paper tickets to electronic trading, and the NYSE’s evolution through decades of technological change.

Our TOPPODCAST Picks

Follow Us

Stay Connected

Related Podcasts

Links

Stay Connected